摘要 |
<p>The present invention relates to the use of at least one antibody, or a functional fragment thereof, which is capable of binding to the protein CXCR4 and thereby inhibiting tumour growth, in the preparation of a medicament intended for the treatment of cancer. The invention is also directed to a composition for the treatment of cancer, comprising, as active ingredient, at least one anti-CXCR4 antibody, or a functional fragment thereof, which is capable of binding to the protein CXCR4 and/or of inhibiting its angiogenic and/or proliferative activity. More especially, said antibodies consist of the antibody MAB173.</p> |